What Researchers Did
Researchers described one of the earliest reported uses of recombinant human platelet-derived growth factor-BB (rhPDGF) gel to improve the healing of a previously irradiated, refractory dermal wound on the neck that had persisted for 12 years.
What They Found
A 47-year-old man with a 12-year history of a non-healing neck wound following radiation therapy received topical rhPDGF gel treatment. After 6 months, sufficient granulation tissue developed, enabling a successful split-thickness skin graft, and the patient's continuous pain resolved.
What This Means for Canadian Patients
This case suggests that recombinant human platelet-derived growth factor-BB gel may offer a potential treatment option for Canadian patients with chronic, previously irradiated wounds unresponsive to other therapies. However, more extensive research is needed to confirm its efficacy and safety across a broader patient population.
Canadian Relevance
This study has no direct Canadian connection as it was conducted outside of Canada and did not involve Canadian researchers or patients.
Study Limitations
As a single case report, this study's findings cannot be generalized to a wider patient population and require further investigation through larger clinical trials.